Ultrasound abnormalities and additional pulmonary function test changes present in 16 percent of cases, indicating ILI
FRIDAY, Dec. 6, 2024 (HealthDay News) — For asymptomatic rheumatoid arthritis (RA) patients, a new radiation-free screening protocol can identify suspected interstitial lung involvement (ILI), according to a study published online Nov. 23 in BMC Pulmonary Medicine.
Frank Reichenberger, M.D., from Augustinum Hospital Munich, and colleagues proposed a noninvasive, radiation-free approach to ILI screening using pulmonary function tests (PFT) and pleuro-pulmonary transthoracic ultrasound (LUS) with additional cardiopulmonary exercise tests with electrocardiography and echocardiography. The study included 67 consecutive patients with a confirmed diagnosis of seropositive RA, without symptoms for or known cardiovascular disease. When significant LUS abnormalities and additional PFT changes were present, interstitial lung disease (ILD) was suspected.
The researchers found that 40 percent of patients had noticeable changes in LUS, 24 percent with a pattern compatible with ILD. LUS abnormalities and additional PFT changes were present in 16 percent of cases, and ILI was suspected. Obstructive lung disease; subpleural consolidation, including one confirmed lung cancer; minimal pleural effusion; and ischemic cardiac disease were included as additional findings (11, six, six, and two patients, respectively). Pulmonary vascular involvement was not seen in any of the patients.
“Our study supports the growing evidence and experience in using LUS for screening for RA-ILD,” the authors write. “We propose LUS as an appropriate imaging tool in combination with PFT for ILD screening in RA.”
The study was funded by Boehringer Ingelheim.
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
Rheumatic Immune-Related AEs With Immune Checkpoint Inhibitors More Severe Than Previously Reported
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
Distinct Characteristics ID"d for Patients With Rheumatoid Conditions, Opioid Use Disorder
Withdrawal From Medetomidine Increasingly Seen in ICUs
Considerable Gaps Reported in Care for Youth With Opioid Use Disorder
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Low Hydroxychloroquine Intake, Blood Levels Linked to ASCVD Risk in Lupus